EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY-NC 4.0

Efficacy and Safety of Chinese Herbal Medicine in Patients with Acute Intracerebral Hemorrhage: Protocol for a Randomized Placebo-Controlled Double-Blinded Multicenter Trial

Yang Zhao, Wanzhen Cui, Tingting Xie, Kai Zhao, Yunke Li, Yingfeng Wan, Xia Wang, Qiang Li, Chen Xiaoying, Zhenchuan Liu, Haining Zhao, Baoying Gong und 13 weitere

Cerebrovascular Diseases · 2024

DOI: 10.1159/000534761 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Cerebrovascular Diseases, 2024. Verfasst von Yang Zhao und 24 weiteren Autor:innen. Beteiligte Einrichtung: The George Institute for Global Health China, Beijing, China. Hauptthemen laut MEDLINE: Cerebral Hemorrhage, Drugs, Chinese Herbal, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The popular traditional Chinese medicine (TCM) compound FYTF-919 (Zhong Feng Xing Nao prescription) may improve outcome from acute intracerebral hemorrhage (ICH) through effects on brain edema, hematoma absorption, and the immune system. This study is to assess whether FYTF-919 is safe and effective as compared to matching placebo treatment in patients with acute ICH.

Methods

The ongoing Chinese Herbal medicine in patients with Acute INtracerebral hemorrhage (CHAIN) is a multicenter, prospective, randomized, double-blind placebo-controlled trial of FYTF-919 in patients with acute ICH at 20–30 hospital sites in China. Eligible ICH patients presenting within 48 h after symptom onset are randomly allocated to receive either FYTF-919 (100 mL per day × 28 d, oral) or matching placebo. A sample size of 1,504 patients is estimated to provide 90% power (α 0.05) to detect a ≥20% improvement in average utility-weight scores on the modified Rankin scale (UW-mRS) assessed at 90 days, with 6% non-adherence and 10% lost to follow-up. The primary efficacy outcome is UW-mRS at 90 days. Secondary outcomes include binary measures of the mRS, neurological impairment on the National Institute of Health Stroke Scale, and health-related quality of life on the EuroQol EQ-5D-5L scale at different time points over 6 months of follow-up. The key safety measure is serious adverse events.

Conclusion

CHAIN is on schedule to provide reliable evidence over the benefits of a popular herbal TCM for the treatment of acute ICH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cerebral HemorrhageDrugs, Chinese HerbalRandomized Controlled Trials as TopicAdultAgedFemaleHumansMaleMiddle AgedAcute DiseaseChinaDisability EvaluationDouble-Blind MethodFunctional StatusMulticenter Studies as TopicProspective StudiesRecovery of FunctionTime FactorsTreatment Outcome

Stichwörter der Autor:innen

Chinese herbal medicineIntracerebral hemorrhageOutcomeRandomized controlled trialStroke

Substanzen

Drugs, Chinese Herbal

Autor:innen und Institutionen

  • The George Institute for Global Health China, Beijing, China.
  • The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
  • The Second Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China, wanzhencc@163.com.
  • Neurology Department, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Research Team of Prevention and Treatment of Cerebral Hemorrhage Applying Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Liaoning Thrombus Treatment Center of Integrated Chinese and Western Medicine, Shenyang, China.

Zitieren

APA

Zhao, Y., Cui, W., Xie, T., Zhao, K., Li, Y., Wan, Y., Wang, X., Li, Q., Xiaoying, C., Liu, Z., Zhao, H., Gong, B., Wang, R., Wu, M., Wang, D., Zheng, Y., Chen, Y., Chen, Y., Guo, Q., …, & for CHAIN investigators (2024). Efficacy and Safety of Chinese Herbal Medicine in Patients with Acute Intracerebral Hemorrhage: Protocol for a Randomized Placebo-Controlled Double-Blinded Multicenter Trial. Cerebrovascular Diseases. https://doi.org/10.1159/000534761

Vancouver

Zhao Y, Cui W, Xie T, Zhao K, Li Y, Wan Y, et al. Efficacy and Safety of Chinese Herbal Medicine in Patients with Acute Intracerebral Hemorrhage: Protocol for a Randomized Placebo-Controlled Double-Blinded Multicenter Trial. Cerebrovascular Diseases. 2024. doi:10.1159/000534761

BibTeX
@article{Zhao2024,
  author = {Zhao, Yang and Cui, Wanzhen and Xie, Tingting and Zhao, Kai and Li, Yunke and Wan, Yingfeng and Wang, Xia and Li, Qiang and Xiaoying, Chen and Liu, Zhenchuan and Zhao, Haining and Gong, Baoying and Wang, Ruihua and Wu, Manli and Wang, Dou and Zheng, Yanwen and Chen, Yanjia and Chen, Yue and Guo, Qihua and Gan, Changlian and Che, Fengyuan and Song, Lili and Anderson, Craig S and Guo, Jianwen and for CHAIN investigators, for CHAIN investigators},
  title = {Efficacy and Safety of Chinese Herbal Medicine in Patients with Acute Intracerebral Hemorrhage: Protocol for a Randomized Placebo-Controlled Double-Blinded Multicenter Trial},
  journal = {Cerebrovascular Diseases},
  year = {2024},
  doi = {10.1159/000534761}
}
Kostenlos starten →